Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18210130 | 1.00 | MAPT (0.38) | MAPTGAATSHRMMP2ANPEP | |
| SCHEMBL21178535 | 1.00 | MAPT (0.38) | MAPTGAATSHRMMP2ANPEP | |
| SCHEMBL22609902 | 1.00 | MAPT (0.38) | MAPTGAATSHRMMP2ANPEP | |
| SCHEMBL376571 | 1.00 | MAPT (0.38) | MAPTGAATSHRMMP2ANPEP | |
| Hydrochloric Acid SCHEMBL18185204 | 0.98 | MAPT (0.36) | MAPTGAATSHRMMP2ANPEP | |
| SCHEMBL21110991 | 0.81 | MMP2 (0.42) | MAPTGAATSHRMMP2ANPEP | |
| SCHEMBL17842674 | 0.81 | MMP2 (0.42) | MAPTGAATSHRMMP2ANPEP | |
| SCHEMBL1923044 | 0.81 | MMP2 (0.42) | MAPTGAATSHRMMP2ANPEP | |
| SCHEMBL743865 | 0.81 | MMP2 (0.42) | MAPTGAATSHRMMP2ANPEP | |
| SCHEMBL10002327 | 0.81 | MMP2 (0.42) | MAPTGAATSHRMMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | MEDIC LIFE SCIENCES, INC. | 2024-02-01 | — | — | US | disclosed |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-12-09 | — | — | US | disclosed |
| CN-113677346-A | Inhibitors of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113226306-A | Methods of treating cancer in a patient identified by a biomarker using a non-covalent inhibitor of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3740207-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CCNI, CDK17 | MAPT 3440/4885GAA 2827/4885TSHR 3387/4885 |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | MAPT 215/4885GAA 2580/4885TSHR 2988/4885 |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | MAPT 215/4885GAA 2580/4885TSHR 2988/4885 |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | CDK7, CDK1, CDK17 | MAPT 373/4885GAA 1476/4885TSHR 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.